Arvinas (ARVN) Receivables (2017 - 2026)
Arvinas (ARVN) recorded quarterly Receivables of $6.4 million in Q1 2026, up 42.22% quarter-over-quarter from $4.5 million in Q4 2025, and down 23.81% on a YoY basis from $8.4 million in Q1 2025.
Arvinas (ARVN) Receivables (2017 - 2026) Analysis & Trends
Arvinas' Receivables history runs 10 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Receivables fell 23.81% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (down 23.81% YoY), while the FY2025 annual figure was $4.5 million, down 67.15% from the prior year.
- Receivables was $6.4 million for Q1 2026 at Arvinas, up from $4.5 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $24.0 million in Q3 2025 to a low of $4.5 million in Q4 2025.
- Historically, Receivables has averaged $10.7 million across 5 years, with a median of $9.4 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Receivables surged 146.94% in 2022, then slumped 66.67% in 2025.
- A 5-year view of Receivables shows it stood at $11.7 million in 2022, then decreased by 19.66% to $9.4 million in 2023, then soared by 43.62% to $13.5 million in 2024, then tumbled by 66.67% to $4.5 million in 2025, then surged by 42.22% to $6.4 million in 2026.
- The last three Receivables figures came in at $6.4 million (Q1 2026), $4.5 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 6.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 8.40 Mn |
| Dec 31, 2024 | 13.50 Mn |
| Sep 30, 2024 | 16.10 Mn |
| Jun 30, 2024 | 11.80 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | 9.40 Mn |
| Sep 30, 2023 | 20.60 Mn |
| Jun 30, 2023 | 4.80 Mn |
| Mar 31, 2023 | 4.70 Mn |
| Dec 31, 2022 | 11.70 Mn |
| Sep 30, 2022 | 12.20 Mn |
| Jun 30, 2022 | 8.10 Mn |
| Mar 31, 2022 | 12.10 Mn |
| Dec 31, 2021 | 27.50 Mn |
| Sep 30, 2021 | 14.70 Mn |
| Jun 30, 2021 | 4.90 Mn |